Printer Friendly

ATLAB Pharma, BZL Biologics sign agreement for radiopharmaceutical Lu-J591.

M2 PHARMA-October 31, 2011-ATLAB Pharma, BZL Biologics sign agreement for radiopharmaceutical Lu-J591(C)2011 M2 COMMUNICATIONS

31 October 2011 - French biotech ATLAB Pharma SAS and US BZL Biologics LLC have signed an exclusive sublicence agreement to develop, manufacture and distribute 177Lu-J591, a radiopharmaceutical for cancer treatment.

Under the agreement, the partners will perform a Phase IIb/III clinical validation programme. ATLAB will fund certain product development and clinical studies.

So far, 177Lu-J591 has been tested in Phase I and Phase II trials in 108 patients with metastatic castrate-resistant prostate cancer (M+ CRPC) and it has proved to be well tolerated and with attractive efficacy.

A multi-centre, randomised Phase IIb clinical trial is currently in progress to test the drug in castrate-resistant prostate cancer (CRPC) patients with rising PSA but no detectable metastasis (M0CRPC).

((Comments on this story may be sent to

COPYRIGHT 2011 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2011 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Oct 31, 2011
Previous Article:Auxilium net loss srinks to USD4.1m in Q3 2011.
Next Article:Endo to relocate head office.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters